RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors
December 10 2019 - 8:00AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced that Mary Ann Gray, Ph.D.,
President of Gray Strategic Advisors, LLC, has joined its Board of
Directors.
“We are pleased to welcome Mary Ann to our Board, as she brings
a wealth of scientific and financial expertise from her time
investing in and covering biotech companies, as well as broad
leadership experience guiding companies as they develop key
therapeutics with a wide range of pharmacological applications,”
said Brian Wong, M.D., Ph.D., President and CEO of RAPT
Therapeutics. “We believe Mary Ann will offer both scientific and
business insights as we continue to grow the company and advance
FLX475 for the treatment of multiple cancers and RPT193 for the
treatment of allergic inflammatory diseases.”
Dr. Gray is President of Gray Strategic Advisors, LLC, a
biotechnology strategic planning and advisory firm. Previously, she
served as Senior Analyst and Portfolio Manager of Federated
Kaufmann Fund where she was responsible for over $1 billion in
healthcare investments including biotechnology, specialty
pharmaceutical, pharmaceutical and healthcare services companies.
Prior to Federated, she served as a biotechnology equity research
analyst at multiple firms. Earlier in her career, she worked as a
senior scientist both at Schering Plough Research and NeoRx
Corporation. She currently serves on the boards of Seneca Biopharma
Inc. and Sarepta Therapeutics, Inc. and previously served on the
board of many public and private biotech companies. Dr. Gray holds
a Bachelor of Science degree from the University of South
Carolina, a Ph.D. in pharmacology from the University of
Vermont, and completed her post-doctoral work at Northwestern
University Medical School and at the Yale University
School of Medicine.
“RAPT Therapeutics, with its integrated platform for drug
discovery, has the potential to truly disrupt the treatment
paradigm for multiple disease areas – from cancer to inflammation,”
commented Dr. Gray. “I look forward to working with the executive
team and Board at this pivotal time for the Company, with exciting
data readouts from both lead programs expected by mid-2020.”
About RAPT Therapeutics, Inc.RAPT Therapeutics
(formerly FLX Bio) is a clinical stage immunology-based
biopharmaceutical company focused on discovering, developing and
commercializing oral small molecule therapies for patients with
significant unmet needs in oncology and inflammatory diseases.
Utilizing its proprietary discovery and development engine, the
company is developing highly selective small molecules designed to
modulate the critical immune responses underlying these diseases.
In its first four years since inception, RAPT has discovered and
advanced two unique drug candidates, each targeting C-C motif
chemokine receptor 4 (CCR4). The Company’s lead oncology drug
candidate, FLX475, reached the clinic in just two and a half years
and its lead inflammation drug candidate, RPT193, is also in the
clinic. The Company is also pursuing a range of targets, including
general control nonderepressible 2 and hematopoietic progenitor
kinase 1, that are in the discovery stage of development.
Forward-Looking StatementsThis press release
contains forward-looking statements. These statements relate to
future events and involve known and unknown risks, uncertainties
and other factors which may cause our actual results, performance
or achievements to be materially different from any future
performances or achievements expressed or implied by the
forward-looking statements. Each of these statements is based only
on current information, assumptions and expectations that are
inherently subject to change and involve a number of risks and
uncertainties. Forward-looking statements include, but are not
limited to, statements about the clinical development of FLX475 and
RPT193. Detailed information regarding factors that may cause
actual results to differ materially from the results expressed or
implied by statements in this press release may be found in RAPT’s
final prospectus filed with the Securities and Exchange Commission
on November 1, 2019. These forward-looking statements speak only as
of the date hereof. RAPT disclaims any obligation to update these
forward-looking statements.
RAPT Media Contact:Angela Bittingmedia@rapt.com(925)
202-6211
RAPT Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024